Comparing Individualized Survival Predictions From Random Survival Forests and Multistate Models in the Presence of Missing Data: A Case Study of Patients With Oropharyngeal Cancer

被引:0
|
作者
Abbott, Madeline R. [1 ]
Beesley, Lauren J. [1 ,2 ]
Bellile, Emily L. [1 ]
Shuman, Andrew G. [3 ]
Rozek, Laura S. [4 ]
Taylor, Jeremy M. G. [1 ]
机构
[1] Univ Michigan, Dept Biostat, 1415 Washington Hts, Ann Arbor, MI 48109 USA
[2] Los Alamos Natl Lab, Informat Syst & Modeling, Los Alamos, NM USA
[3] Univ Michigan, Dept Otolaryngol, Ann Arbor, MI 48109 USA
[4] Georgetown Univ, Dept Oncol, Sch Med, Washington, DC USA
关键词
Survival analysis; multistate model; random survival forest; predictive accuracy; cancer application; missing data;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: In recent years, interest in prognostic calculators for predicting patient health outcomes has grown with the popularity of personalized medicine. These calculators, which can inform treatment decisions, employ many different methods, each of which has advantages and disadvantages. Methods: We present a comparison of a multistate model (MSM) and a random survival forest (RSF) through a case study of prognostic predictions for patients with oropharyngeal squamous cell carcinoma. The MSM is highly structured and takes into account some aspects of the clinical context and knowledge about oropharyngeal cancer, while the RSF can be thought of as a black-box non-parametric approach. Key in this comparison are the high rate of missing values within these data and the different approaches used by the MSM and RSF to handle missingness. Results: We compare the accuracy (discrimination and calibration) of survival probabilities predicted by both approaches and use simulation studies to better understand how predictive accuracy is influenced by the approach to (1) handling missing data and (2) modeling structural/disease progression information present in the data. We conclude that both approaches have similar predictive accuracy, with a slight advantage going to the MSM. Conclusions: Although the MSM shows slightly better predictive ability than the RSF, consideration of other differences are key when selecting the best approach for addressing a specific research question. These key differences include the methods' ability to incorporate domain knowledge, and their ability to handle missing data as well as their interpretability, and ease of implementation. Ultimately, selecting the statistical method that has the most potential to aid in clinical decisions requires thoughtful consideration of the specific goals.
引用
收藏
页数:16
相关论文
共 50 条
  • [41] Comparison of tumor size assessments in tumor growth inhibition-overall survival models with second-line colorectal cancer data from the VELOUR study
    Claret, Laurent
    Pentafragka, Christina
    Karovic, Sanja
    Zhao, Binsheng
    Schwartz, Lawrence H.
    Maitland, Michael L.
    Bruno, Rene
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (01) : 49 - 54
  • [42] Comparison of tumor size assessments in tumor growth inhibition-overall survival models with second-line colorectal cancer data from the VELOUR study
    Laurent Claret
    Christina Pentafragka
    Sanja Karovic
    Binsheng Zhao
    Lawrence H. Schwartz
    Michael L. Maitland
    Rene Bruno
    Cancer Chemotherapy and Pharmacology, 2018, 82 : 49 - 54
  • [43] FOLFIRINOX (F-NOX) followed by individualized radiation for borderline-resectable pancreatic cancer (BRPC): Toxicity, RO resection, and interim survival data from a prospective phase II study.
    Murphy, Janet E.
    Wo, Jennifer Yon-Li
    Ryan, David P.
    Jiang, Wenqing
    Yeap, Beow Y.
    Drapek, Lorraine C.
    Blaszkowsky, Lawrence Scott
    Kwak, Eunice Lee
    Allen, Jill N.
    Clark, Jeffrey W.
    Faris, Jason Edward
    Zhu, Andrew X.
    Goyal, Lipika
    Mamon, Harvey J.
    Wolpin, Brian M.
    Lillemoe, Keith D.
    DeLaney, Thomas F.
    Fernandez-del Castillo, Carlos
    Ferrone, Cristina
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [44] Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from colorectal cancer: A case-control study from a Chinese center
    Huang, Chao-Qun
    Feng, Jue-Ping
    Yang, Xiao-Jun
    Li, Yan
    JOURNAL OF SURGICAL ONCOLOGY, 2014, 109 (07) : 730 - 739
  • [45] Survival outcomes in patients with advanced non-small cell lung cancer treated with erlotinib: expanded access programme data from Belgium (the TRUST study)
    Van Meerbeeck, J.
    Galdermans, D.
    Bustin, F.
    De Vos, L.
    Lechat, I.
    Abraham, I.
    EUROPEAN JOURNAL OF CANCER CARE, 2014, 23 (03) : 370 - 379
  • [46] Construction of Predictive Models for Cancer-specific Survival of Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guerin: Results from a Multicenter Retrospective Study
    Nishiyama, Naotaka
    Kitamura, Hiroshi
    Hotta, Hiroshi
    Takahashi, Atsushi
    Yanase, Masahiro
    Itoh, Naoki
    Tachiki, Hitoshi
    Miyao, Noriomi
    Matsukawa, Masanori
    Kunishima, Yasuharu
    Taguchi, Keisuke
    Masumori, Naoya
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 44 (11) : 1101 - 1108
  • [47] Adherence with National Comprehensive Cancer Network (NCCN) Guidelines Associated with improved survival in ovarian cancer patients, a study of 144,449 patients from the National Cancer Data Base: A project from the Society of Gynecologic Oncologists (SGO) Quality and Outcomes Committee
    Powell, M.
    Cliby, W.
    Bristow, R.
    Al-Hammadi, N.
    Chen, L.
    Miller, J.
    Roland, P.
    Mutch, D.
    GYNECOLOGIC ONCOLOGY, 2011, 121 (02) : S1 - S2
  • [48] Impact of post-progression anti-vascular endothelial growth factor-containing therapy on survival in patients with metastatic colorectal cancer: Data from the PRIME study
    Peeters, M.
    Douillard, J. Y.
    Siena, S.
    Price, T.
    Tabernero, J.
    Sidhu, R.
    Braun, S.
    Davison, C.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S18 - S18
  • [49] Hand-foot syndrome and survival in patients with advanced non-small-cell lung cancer receiving anlotinib: a subgroup analysis of data from the ALTER 0303 study
    Nan, Xueli
    Xie, Chao
    Zhu, Qingqing
    Zhang, Jianjun
    Fu, Shuai
    Han, Xiao
    Zhang, Qiujing
    Han, Baohui
    Liu, Jie
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (08) : 1492 - 1498
  • [50] Hand-foot syndrome and survival in patients with advanced non-small-cell lung cancer receiving anlotinib: a subgroup analysis of data from the ALTER 0303 study
    Xueli Nan
    Chao Xie
    Qingqing Zhu
    Jianjun Zhang
    Shuai Fu
    Xiao Han
    Qiujing Zhang
    Baohui Han
    Jie Liu
    International Journal of Clinical Oncology, 2020, 25 : 1492 - 1498